Stem cell transplantation: autologous or allogeneic, and what can go wrong
- Treatment and support
A stem cell transplant replaces a damaged or cancerous marrow. Knowing whose cells are given predicts the risks, from infections to graft-versus-host disease.
What it is
Haematopoietic stem cell transplantation gives blood-forming stem cells after conditioning treatment. In an autologous transplant the patient's own cells, collected beforehand, rescue the marrow after very intensive chemotherapy. In an allogeneic transplant cells come from a donor (a matched sibling, a matched unrelated donor, a half-matched relative or cord blood) and bring a new immune system that can attack residual cancer (graft-versus-leukaemia) but also the patient's tissues (graft-versus-host disease, GvHD). Cells are collected from blood after mobilisation, from the marrow, or from umbilical cord blood.
What to know
- Typical autologous uses: multiple myeloma and relapsed lymphoma (and some others); no GvHD and no graft-versus-leukaemia effect.
- Typical allogeneic uses: high-risk or relapsed acute leukaemias, MDS, myelofibrosis, CML that fails TKIs, severe aplastic anaemia, and inherited diseases such as sickle cell disease and thalassaemia major.
- Donor matching relies on HLA; a sibling has a one-in-four chance of being fully matched, and half-matched (haploidentical) family donors have widened access.
- Conditioning is myeloablative (kills the marrow) or reduced-intensity (relies more on the donor immune system, gentler for older or frailer patients).
- Engraftment is the recovery of neutrophils from the new cells, usually 2 to 4 weeks after infusion; platelets recover later.
- Acute GvHD hits the skin (rash, often palms and soles), liver (cholestatic jaundice) and gut (diarrhoea); chronic GvHD resembles autoimmune disease (dry eyes and mouth, skin tightening, lung scarring).
How it is done (and why)
- Collect: mobilise stem cells into the blood with growth factor and collect by apheresis (or harvest marrow, or use cord blood); store autologous cells frozen.
- Condition: chemotherapy, with or without radiotherapy, kills the disease, makes space and, in allogeneic transplants, stops the host rejecting the graft.
- Infuse the cells through a central line, like a transfusion; they find their way to the marrow.
- Support through aplasia: neutropenic precautions, antimicrobial prophylaxis, irradiated blood products, nutrition and care of mucositis.
- Engraft: neutrophils return; in allogeneic transplants continue immunosuppression to prevent GvHD.
- Follow for months to years: CMV and other infection surveillance, GvHD, chimerism, revaccination and late effects.
Autologous versus allogeneic
| Feature | Autologous | Allogeneic |
|---|---|---|
| Source of cells | Patient's own, collected before | Donor: sibling, unrelated, half-matched relative, cord blood |
| What cures the disease | The high-dose chemotherapy | Conditioning plus the donor immune system (graft-versus-leukaemia) |
| GvHD | No | Yes, acute and chronic |
| Rejection | No | Possible (graft failure) |
| Infection risk | Mainly during the weeks of aplasia | Higher and longer: immunosuppression, GvHD, viruses such as CMV |
| Treatment-related mortality | Low | Higher; varies with age, donor and conditioning |
Risks and precautions
- Infections follow a timeline: in the aplasia, bacteria, Candida, Aspergillus and herpes simplex; in the first months, CMV, Pneumocystis and adenovirus; later, encapsulated bacteria and varicella-zoster, especially with chronic GvHD.
- Fever in the first weeks is febrile neutropenia until proven otherwise: start empirical intravenous antibiotics within the hour.
- Painful enlarged liver, jaundice and weight gain from fluid in the first weeks suggest sinusoidal obstruction syndrome (veno-occlusive disease) after conditioning.
- All cellular blood products after transplant are irradiated, to prevent transfusion-associated GvHD; after an ABO-mismatched transplant the blood group changes to the donor's, so the blood bank must know.
- The immune memory is lost: patients are revaccinated from scratch, and live vaccines wait until immunity has recovered.
Monitoring and next step
- Daily count during aplasia; engraftment is the first of several days with neutrophils above 0.5 × 10⁹/L.
- CMV PCR weekly in at-risk allogeneic recipients, with prophylaxis (letermovir) or pre-emptive treatment (ganciclovir or valganciclovir, which suppress the marrow).
- Drug levels of calcineurin inhibitors (ciclosporin, tacrolimus), plus kidney function, magnesium and blood pressure.
- Chimerism (the share of donor cells in blood and marrow) and disease markers to detect graft failure or relapse.
- Suspected GvHD: skin, liver or gut biopsy when the diagnosis is uncertain; steroids are first line and ruxolitinib for steroid-refractory disease.
Common traps
- Thinking an autologous transplant cures by the graft: the cells only rescue the marrow; the cure is the chemotherapy.
- Giving non-irradiated blood products to a transplant recipient: transfusion-associated GvHD is almost always fatal.
- Attributing diarrhoea after an allogeneic transplant to an infection only: it may be gut GvHD (and vice versa: rule out CMV and Clostridioides difficile).
- Giving a live vaccine too early after transplant: live vaccines have to wait.
- Assuming the blood group is the same as before an ABO-mismatched transplant: after it the group is no longer the same.
Test yourself
Think of the answer, then tap the question to see it.
Why does a patient with acute myeloid leukaemia receive an allogeneic rather than an autologous transplant?
Because the donor immune system attacks remaining leukaemia cells (graft-versus-leukaemia), and the patient's own marrow may still carry the leukaemia.
Which three organs does acute GvHD typically involve?
Skin (a rash, often on palms and soles), liver (cholestatic jaundice) and gut (diarrhoea, which can be profuse).
Why are all cellular blood products irradiated for a transplant recipient?
Irradiation stops donor lymphocytes in the bag from multiplying and attacking a host that cannot reject them (transfusion-associated GvHD).
Two months after an allogeneic transplant, which virus is watched for by weekly PCR, and why?
Cytomegalovirus: reactivation is common under immunosuppression and can cause pneumonitis, colitis and marrow suppression, so it is treated before disease appears.
Elsewhere in DurgiPedia
- Haematopoietic stem cell transplant: the immunology
- Graft-versus-host disease: the immunology
- HLA inheritance, typing and the crossmatch
- Leukaemia, lymphoma and stem-cell transplant: nursing care and graft-versus-host warning signs
- The neutropenic and immunosuppressed patient (nursing)
Connections
Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.
Sources: Stem Cell Transplants in Cancer Treatment (National Cancer Institute, 2024); Bone marrow transplant: MedlinePlus Medical Encyclopedia (U.S. National Library of Medicine, 2026); Graft-versus-host disease (MedlinePlus, U.S. National Library of Medicine, 2026); Bone marrow transplant - discharge: MedlinePlus Medical Encyclopedia (MedlinePlus, US National Library of Medicine, 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
